Cognition Therapeutics (NASDAQ:CGTX) Price Target Raised to $6.00 at HC Wainwright

Cognition Therapeutics (NASDAQ:CGTX) had its target price lifted by HC Wainwright from $5.00 to $6.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Chardan Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Cognition Therapeutics in a research report on Thursday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Cognition Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $8.30.

Cognition Therapeutics Trading Down 3.8 %

Shares of Cognition Therapeutics stock traded down $0.02 on Thursday, reaching $0.61. 2,507,341 shares of the company were exchanged, compared to its average volume of 2,060,611. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The company has a 50-day moving average of $0.47 and a 200 day moving average of $0.94. The company has a market capitalization of $25.35 million, a price-to-earnings ratio of -0.63 and a beta of 1.26.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGTX. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics during the 3rd quarter worth $27,000. Sigma Planning Corp lifted its stake in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the last quarter. CM Management LLC increased its holdings in shares of Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after acquiring an additional 24,050 shares during the last quarter. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.